Company intelligence / Profile preview

Cibus, Inc.

San Diego, California, United Statescibus.com ↗

Ownership: Public · CBUS
Development stage: Commercial

Overview

Cibus has developed a proprietary gene-editing platform that enables rapid development of new plant traits without introducing foreign DNA. The company has achieved milestones such as developing durable white mold resistance in canola and advancing weed management traits in rice. Its technology allows delivery of edited traits into elite germplasm within 12 months—significantly faster than traditional breeding—and its products are regulated similarly to conventional crops due to their non-transgenic nature.

Therapeutic areas: Other
Modalities: Gene editing
Industry: Agriculture & AgTech

Partnerships

Seed companies licensing RTDS-developed traits for commercializationStrategic investors from recent public offering may also be partners

Beyond the preview

Go deeper on Cibus, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cibus, Inc..

Explore the full profile